Neuraly
Neuraly is a biotech company. It has raised $36.0M across 1 round, most recently a $36.0M Series A in July 2018.
- Website
- neuralymed.com
- Total Funding
- $36.0M
- Last Round
- $36.0M Series AJul 2018
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 1 funding round and 5 investors for this company. The full record is or through the API.
About
Neuraly develops new drugs intended to improve the treatment of progressive diseases, including Alzheimer’s disease and Parkinson’s disease.
Summary
It has raised $36.0M in total across 1 round, most recently a $36.0M Series A round in Jul 2018. Investors include Octave Life Sciences, Smilegate Investment and InterVest Capital Partners.
Funding History
Jul 2018
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/neuraly"><img src="https://indexed.vc/api/badge/company/neuraly" alt="Neuraly on Indexed.vc" width="260" height="76" /></a>